AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. More Details
High growth potential with imperfect balance sheet.
Share Price & News
How has AcelRx Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ACRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ACRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: ACRX underperformed the US Pharmaceuticals industry which returned 8.9% over the past year.
Return vs Market: ACRX underperformed the US Market which returned 53.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is AcelRx Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWhat Type Of Returns Would AcelRx Pharmaceuticals'(NASDAQ:ACRX) Shareholders Have Earned If They Purchased Their Shares Five Years Ago?
2 months ago | Simply Wall StWhen Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Turn A Profit?
5 months ago | Simply Wall StAnalysts Are Upgrading AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) After Its Latest Results
Is AcelRx Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether AcelRx Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AcelRx Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is AcelRx Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ACRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ACRX's is expected to become profitable in the next 3 years.
Revenue vs Market: ACRX's revenue (49.7% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ACRX's revenue (49.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACRX is forecast to be unprofitable in 3 years.
How has AcelRx Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACRX is currently unprofitable.
Growing Profit Margin: ACRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACRX is unprofitable, and losses have increased over the past 5 years at a rate of 7.7% per year.
Accelerating Growth: Unable to compare ACRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).
Return on Equity
High ROE: ACRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is AcelRx Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ACRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ACRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ACRX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ACRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ACRX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 9.2% each year.
What is AcelRx Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vince Angotti (52 yo)
Mr. Vincent J. Angotti, also known as Vince, has been the Chief Executive Officer of AcelRx Pharmaceuticals, Inc. since March 6, 2017. Mr. Angotti served as the Chief Executive Officer of Xenoport, Inc. si...
CEO Compensation Analysis
Compensation vs Market: Vince's total compensation ($USD2.13M) is above average for companies of similar size in the US market ($USD543.87K).
Compensation vs Earnings: Vince's compensation has increased whilst the company is unprofitable.
Experienced Management: ACRX's management team is seasoned and experienced (13.6 years average tenure).
Experienced Board: ACRX's board of directors are considered experienced (9.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.9%.
AcelRx Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AcelRx Pharmaceuticals, Inc.
- Ticker: ACRX
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$102.308m
- Shares outstanding: 118.95m
- Website: https://www.acelrx.com
Number of Employees
- AcelRx Pharmaceuticals, Inc.
- 351 Galveston Drive
- Redwood City
- United States
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company’s lead product candidate is DSUV...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/17 23:40|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.